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Reactive oxygen intermediates mediate brain injury in bacterial meningitis. Several anti-
oxidant drugs are clinically available, including N-acetylcysteine (NAC), deferoxamine (DFO),
and trylizad-mesylate (TLM). The present study evaluated whether these antioxidants are
beneficial in a model of pneumococcal meningitis. Eleven-day-old rats were infected intracis-
ternally with Streptococcus pneumoniae and randomized to intraperitoneal treatment every 8
h with NAC (200 mg/kg), DFO (100 mg/kg), TLM (10 mg/kg), or saline (250 mL). TLM-
treated animals showed a significantly reduced mortality compared with controls ( ).P ! .03
Meningitis led to extensive cortical injury at h after infection (median, 14.6% of22 5 2.2
cortex; range, 0–61.1%). Injury was significantly ( ) reduced to 1.1% (range, 0–34.6%)P ! .01
by NAC, to 2.3% (range, 0–19.6%) by DFO, and to 0.2% (range, 0–36.9%) by TLM (the
difference was not significant among the 3 groups). None of the drugs reduced hippocampal
injury. Thus, several clinically used antioxidants reduced cortical injury in experimental pneu-
mococcal meningitis.
Reactive oxygen intermediates (ROIs), a family of molecules
derived from the partial reduction of molecular oxygen, have
been implicated as mediators of neuronal damage in bacterial
meningitis [1–3]. ROIs are released by the host from stimulated
granulocytes, macrophages, and microglia, and Streptococcus
pneumoniae has been shown to utilize pyruvate oxidase to pro-
duce ROIs. Because of their free radical nature (i.e., the pres-
ence of an unpaired electron) and loss of spin restriction, ROIs
react avidly with organic molecules and are cytotoxic by oxi-
dizing membrane phospholipids, proteins, nucleic acids, and
nucleotides.
A number of factors make the central nervous system par-
ticularly susceptible to oxidative damage. The brain receives
∼20% of the cardiac blood output and thus has a high oxygen
tension, and brain cell membranes are rich in polyunsaturated
fatty acids that can be oxidized by ROIs. Brain tissue has rel-
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atively low levels of endogenous antioxidant defense systems.
In previous studies based upon a model of bacterial meningitis
caused by group B streptococci, we localized the generation of
ROIs to cells of the subarachnoid and ventricular inflammation
and to the cerebral vasculature, the site of blood-brain barrier
breakdown [1].
In an infant rat model of meningitis due to group B strep-
tococci, the spin-trapping agent a-phenyl-tert-butyl nitrone sig-
nificantly attenuated neuronal damage [1]. Other antioxidants
attenuated a number of early events associated with bacterial
meningitis, such as early increases in cerebral blood flow, in-
tracranial pressure, brain water content, cerebrospinal fluid
(CSF) white blood cell count, and pial arteriolar vasodilatation
[4–6].
For the present study, we used an established rat model of
experimental neonatal meningitis due to S. pneumoniae, which
leads to neuronal damage [7, 8]. The model shows features
identical to those described in neonates and infants with neo-
natal meningitis. Two distinct forms of neuronal injury have
been documented: extensive cortical injury and apoptotic injury
to the dentate gyrus of the hippocampus [1].
In this study, we examined the effect of 3 agents that interfere
with ROI production at different stages (figure 1). N-acetyl-
cysteine (NAC), which increases endogenous antioxidant de-
fenses (glutathione), is clinically used for paracetamol intoxi-
cation [4, 9]. Deferoxamine (DFO), an iron-chelating agent,
decreases the concentration of oxidative radicals by inhibiting
the catalyzation of radical production by iron [6, 10]. Trylizad-
mesylate (TLM), which protects cell membranes from peroxi-
dation, is therapeutically used to prevent brain injury in patients
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Figure 1. Formation of reactive oxygen species and antioxidant
mechanisms in biologic systems. Superoxide (O2
2), formed by a one-
electron reduction of molecular O2, is converted to H2O2 by dismutation
and further to OH by the Cu1/Fe21-catalyzed Fenton reaction. The
resultant free radical damage to lipid (peroxidation), proteins, and
DNA leads to various forms of cell injury. The major antioxidant
enzymes are superoxide dismutase, catalase, and glutathione peroxi-
dase. GSH, reduced glutathione; GSSG, oxidized glutathione. As num-
bered in the figure, the antioxidants used for therapy were (1) N-
acetylcysteine (NAC), which increases the endogenous antioxidant
glutathione; (2) deferoxamine (DFO), which decreases the concentra-
tion of oxidative radicals by neutralizing iron; and (3) trylizad-mesylate
(TLM), which inhibits lipid peroxidation.
with subarachnoid-space bleeding [11]. In the present study, we
studied the 3 drugs to explore whether these clinically available
antioxidants should be tested in clinical trials as adjunctive
therapy for bacterial meningitis.
Material and Methods
Model of meningitis. Nursing Sprague-Dawley rats were in-
fected on postnatal day 11 by direct intracisternal injection, with
a 32-gauge needle, of 10 mL of a saline solution containing S.
pneumoniae (serogroup 3), as described elsewhere [7, 8]. The in-
oculum size was log10 cfu/mL. Eighteen hours after6.5 5 0.35
infection, the rats were weighed and assessed clinically for their
ambulatory activity and their ability to right themselves. The oc-
currence of spontaneous seizures was documented during the fol-
lowing 2 h. CSF (1–30 mL) was obtained by puncture of the cisterna
magna. To document meningitis, 10 mL of CSF was cultured quan-
titatively. Starting 18 h after infection, the animals were treated
subcutaneously with 100 mg/kg ceftriaxone. Those surviving 24 h
of infection were killed with an overdose of pentobarbital (100 mg/
kg intraperitoneally). Animals who died unobserved were excluded
from the histopathologic evaluation.
Therapeutics. Three molecular classes of antioxidant agents
were used: NAC (Fluimucil, 20% infusion solution; Inpharzam,
Cadempino, Switzerland), DFO (Sigma, Division of Fluka Chemie,
Buchs, Switzerland), and TLM (Freedox, 150-mg sterile solution;
Pharmacia and Upjohn, Du¨bendorf, Switzerland). Therapy was
begun at the time of infection and was given every 8 h. The NAC
group ( ) received 200 mg/kg, the DFO group ( ) re-n = 24 n = 25
ceived 100 mg/kg, and the TLM group ( ) received 10 mg/kg.n = 25
As a control group, 30 rats received saline. The doses used in this
study correspond to doses from published studies using rat models
of experimental meningitis for NAC [4], a rat model of pneumonia
for DFO [10], and a rat model of the “shaken-baby syndrome” for
TLM [11].
Histopathology. For histopathologic examination, killed ani-
mals were perfused with 4% paraformaldehyde in PBS, and 12
coronal brain sections per animal were evaluated for neuronal in-
jury to the cortex and hippocampus, as described elsewhere [7, 8].
The area of cortical brain damage was expressed as the mean value
per animal of the percentage of the total cortex in each of the 12
sections. Apoptotic death of neurons in the dentate granule cell
layer of the hippocampus was scored, and an averaged score per
animal was calculated from all evaluated sections. All histopath-
ologic evaluations were done by an investigator blinded to the
clinical, microbiologic, and treatment data of the respective animal.
Measurement of tumor necrosis factor–a (TNF-a). The con-
centration of TNF-a in the CSF samples was measured by ELISA
(Cytoscreen Rat Tumor Necrosis Factor–Alpha Ultra Sensitive;
BioSource International, Camarillo, CA) [7]. CSF samples (10 mL)
from infected animals of each study group (NAC, ; DFO,n = 13
; and TLM, ) and from controls ( ) were sampledn = 18 n = 15 n = 15
18 h after infection and immediately centrifuged, and the super-
natant was frozen at 2807C until analyzed, following the manu-
facturer’s instructions.
Statistics. Continuous data were presented as , cat-mean 5 SD
egorical data as median and range. Data not normally distributed
were analyzed by the Kruskal-Wallis test, followed by the Mann-
Whitney test for pairwise comparison. Proportions between groups
were analyzed using Fisher’s exact test. Survival curves were an-
alyzed by Kaplan-Meier analysis for survival data.
Results
Effect of antioxidants on clinical parameters of meningitis.
All infected animals had meningitis, as evidenced by lethargy
or obtundation and by positive bacterial CSF titers at 18 h
after infection. Treatment with NAC and TLM showed no ef-
fect on CSF bacterial titers (table 1). Animals in the DFO
treatment group had lower CSF bacterial titers than animals
in all other groups, which was likely a consequence of growth
inhibition by iron limitation in the CSF. Treatment with anti-
oxidants did not significantly affect the occurrence of seizures
(table 1). However, compared with controls, TLM-treated an-
imals showed a significant ( ) attenuation of spontaneousP ! .03
mortality, while treatment with NAC and DFO had no signif-
icant beneficial effect (table 1).
Effect of antioxidants on CSF concentration of TNF-a. The
CSF concentrations of TNF-a were measured as an indicator
of inflammation. There was no significant difference ( )P 1 .05
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Table 1. Effect of antioxidant treatment on clinical parameters of meningitis.
Group
CSF bacterial titer,
log10 cfu/mL
Occurences of
seizures, %
Spontaneous
death, %
TNF-a in
CSF, ng/mL
Cortical
injury, %
Hippocampal
injury score
Controls 8.20 5 0.54 (28) 50.0 (28) 71.4 (28) 4.8 5 2.9 (15) 14.6 [0–61.1] (28) 0.3 [0–1.08] (18)
NAC 8.17 5 0.57 (23) 30.4 (23) 48.7 (23) 4.9 5 2.6 (13) 1.1 [0–34.6]a (23) 0.3 [0–1.04] (23)
DFO 7.86 5 0.48b (22) 45.5 (22) 59.1 (22) 5.8 5 2.1 (18) 2.3 [0–19.6]c (22) 0.5 [0–1.33] (20)
TLM 8.12 5 0.58 (25) 44.0 (25) 32.0d (25) 4.9 5 2.0 (15) 0.2 [0–36.9]e (25) 0.3 [0–1.17] (22)
NOTE. CSF, cerebrospinal fluid; TNF-a, tumor necrosis factor–a; NAC, N-acetlycysteine; DFO, deferoxamine; TLM,
trylizad-mesylate. CSF bacterial titer and TNF-a in CSF are presented as ; cortical injury and hippocampal injurymean 5 SD
scores are presented as median [range]. Numbers in .parentheses = n
a vs. controls.P ! .02
b vs. controls.P ! .03
c vs. controls.P ! .01
d vs. controls.P ! .03
e vs. controls.P ! .01
between any of the experimental groups at 18 h after infection
(table 1).
Effect of antioxidants on neuronal injury. Two distinct forms
of neuronal injury were identified in this experimental model
of bacterial meningitis. The neurons of the cortex showed mor-
phologic signs that were compatible with necrosis, such as
marked swelling of the cell body and loss of cellular demar-
cation and cytoarchitecture [1]. The injury patterns in the hip-
pocampus were compatible with apoptosis. The occurrence of
apoptosis in the dentate gyrus in this model was confirmed in
a previous study by positive-terminal deoxynucleotidyl trans-
ferase–mediated dUTP nick end labeling (TUNEL) of frag-
mented DNA in the dentate gyrus but not in the cortex [1].
All 3 antioxidants decreased the extent of cortical injury. The
decrease varied from a median of 14.6% (range, 0–61.1%) in
28 control rats to 1.1% (range, 0–34.6%) in 23 NAC-treated
rats ( ), to 2.3% (range, 0–19.6%) in 22 DFO-treated an-P ! .02
imals ( ), and to 0.2% (range, 0–36.9%) in 25 rats treatedP ! .01
with TLM ( ). There were no significant differences inP ! .01
neuroprotective efficacy among the 3 antioxidant therapies (ta-
ble 1).
In contrast, antioxidant treatment had no effect on the extent
of apoptosis in the hippocampus. The median injury score was
0.3 (range, 0–1.04) for the NAC group ( ), 0.5 (range,n = 23
0–1.33) for the DFO group ( ), 0.3 (range, 0–1.17) for then = 20
TLM group ( ), and 0.3 (range, 0–1.08) for the controln = 22
group ( ; table 1).n = 18
Discussion
In the present study, we used an infant rat model to evaluate
the effect of clinically used antioxidants on the clinical and
neuropathological outcomes during pneumococcal meningitis.
We demonstrated that 3 classes of antioxidants (NAC, DFO,
and TLM) that interfere with the harmful effects of ROIs at
different levels exert a neuroprotective effect in the cortex (figure
1). Despite this beneficial effect, we found no reduction of the
inflammatory response (i.e., CSF concentration of TNF-a) or
of hippocampal apoptosis as a result of treatment with any of
the 3 compounds.
We tested the effect of NAC because it has been used as an
antioxidant in a variety of experimental and clinical conditions
[4, 9]. At present, NAC is known to have 2 modes of action:
direct scavenging of free radicals and augmentation of intra-
cellular levels of glutathione [4, 9]. NAC has proven efficacy
as an antioxidant in humans and animals with various diseases,
including experimental bacterial meningitis, in which it signif-
icantly attenuated the increase in brain water content, intra-
cranial pressure, and CSF pleocytosis 24 h after infection [4].
The results of the present study expand these findings by show-
ing a beneficial effect of the drug on cortical injury in neonatal
experimental meningitis. The basis for this beneficial effect is
not completely clear. We have previously documented that
ROIs are generated at the level of the cerebral vasculature and
that cerebral blood flow improved upon treatment with the
radical scavenger a-phenyl-tert-butyl nitrone [1]. Thus, in keep-
ing with the evidence that ischemia contributes to cortical injury
in this model, the neuroprotection of NAC in the cortex might
be mediated by preventing disturbances of cerebral blood flow
[3, 4, 8].
An important factor that contributes to the central nervous
system’s susceptibility to oxidative damage is its rich content
of iron. Extensive experimental support exists for the early oc-
currence and pathophysiologic importance of oxygen radical
formation and cell membrane lipid peroxidation in the injured
nervous system. The radical-initiated peroxidation of neuronal,
glial, and vascular cell membranes and myelin is catalyzed by
free iron released from hemoglobin, transferrin, and ferritin by
lowered tissue pH and oxygen radicals. Thus, a disruption of
the normal iron homeostasis during bacterial meningitis may
lead to an increase in oxygen free radical generation and con-
secutive tissue damage.
DFO was used to evaluate the role of iron in our model of
meningitis. Compounds such as DFO are excellent chelating
agents of free Fe31 and are currently being used clinically to
treat iron-overload patients. In our study, DFO attenuated cor-
tical injury. One possible mechanism for this beneficial effect
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is through inhibition of the Cu1/Fe21-catalyzed Fenton reac-
tion. This would reduce the generation of hydroxyl radicals as
well as that of other reactive products, thus leading to reduced
oxidative damage in the brain [2]. However, more studies are
needed to delineate the exact mechanisms by which DFO exerts
its protective role against ischemia-induced cortical injury in
this model.
The 21-aminosteroid TLM has been shown to be a potent
inhibitor of lipid peroxidation and to reduce traumatic and
ischemic damage in a number of experimental systems [12].
TLM has been shown to decrease the posttraumatic increase
in blood-brain barrier permeability observed after head injury
in rats [12, 13]. As shown by in vitro and in vivo studies, the
efficacy depends on a combination of mechanisms: (1) The
molecules of TLM insert within the lipid bilayer of the cell
membrane, scavenging toxic lipid-peroxyl radicals and reducing
the production of highly reactive hydroxyl radicals [12]; (2) the
insertion of TLM into the cell membrane decreases the
membrane phospholipid fluidity and thereby mitigates the pro-
gression of lipid peroxidation as it spreads across the membrane
[12]; and (3) TLM increases the concentration of vitamin E, an
important endogenous lipophilic antioxidant [14].
Administration of 21-aminosteroids in experimental endo-
toxemia, sepsis, and meningitis showed improvement of sys-
temic and hemodynamic parameters, attenuation of inflam-
mation, preservation of tissue oxygenation, and protection of
endothelial cell integrity [5, 14]. In our model, animals become
invariably bacteremic in the course of the disease and are thus
prone to sepsis, which likely contributes to mortality [7]. TLM,
in contrast to the other antioxidants examined, significantly
attenuated the spontaneous mortality in this study, in keeping
with the known benefits of the drug in sepsis models.
None of the 3 antioxidants studied here attenuated CSF in-
flammation, as measured by the concentration of TNF-a in
CSF. Previous studies found that neurons in the dentate granule
cells of the hippocampus undergo apoptosis during experimen-
tal bacterial meningitis, independent of ischemic damage. This
process is mediated in part by TNF-a [15]. The lack of an effect
of the antioxidant drugs on CSF concentrations of TNF-a is
congruent with the lack of neuroprotection in the hippocampus.
In summary, using a model of bacterial meningitis caused by
S. pneumoniae, we demonstrated a beneficial effect of treatment
with the antioxidants NAC, DFO, and TLM on cortical injury,
whereas the drugs were not efficacious in preventing hippo-
campal injury. Thus, while antioxidant strategies are clearly
promising for the adjunctive therapy of bacterial meningitis, an
ideal drug should act at the level of both the cortex and the
hippocampus.
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